AI's shift to inference at scale from model development is tilting data-center demand toward databases, especially those used ...
The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback